Literature DB >> 22280100

Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.

John D Clarke1, Nathan J Cherrington.   

Abstract

INTRODUCTION: Organic anion transporting polypeptide (OATP) uptake transporters are important for the disposition of many drugs and perturbed OATP activity can contribute to adverse drug reactions (ADRs). It is well documented that both genetic and environmental factors can alter OATP expression and activity. Genetic factors include single nucleotide polymorphisms (SNPs) that change OATP activity and epigenetic regulation that modify OATP expression levels. SNPs in OATPs contribute to ADRs. Environmental factors include the pharmacological context of drug-drug interactions and the physiological context of liver diseases. Liver diseases such as non-alcoholic fatty liver disease, cholestasis and hepatocellular carcinoma change the expression of multiple OATP isoforms. The role of liver diseases in the occurrence of ADRs is unknown. AREAS COVERED: This article covers the roles OATPs play in ADRs when considered in the context of genetic or environmental factors. The reader will gain a greater appreciation for the current evidence regarding the salience and importance of each factor in OATP-mediated ADRs. EXPERT OPINION: A SNP in a single OATP transporter can cause changes in drug pharmacokinetics and contribute to ADRs but, because of overlap in substrate specificities, there is potential for compensatory transport by other OATP isoforms. By contrast, the expression of multiple OATP isoforms is decreased in liver diseases, reducing compensatory transport and thereby increasing the probability of ADRs. To date, most research has focused on the genetic factors in OATP-mediated ADRs while the impact of environmental factors has largely been ignored.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22280100      PMCID: PMC3753226          DOI: 10.1517/17425255.2012.656087

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  83 in total

Review 1.  FDA adverse event reports on statin-associated rhabdomyolysis.

Authors:  Mohamed A Omar; James P Wilson
Journal:  Ann Pharmacother       Date:  2002-02       Impact factor: 3.154

2.  Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

Authors:  L R Brunham; P J Lansberg; L Zhang; F Miao; C Carter; G K Hovingh; H Visscher; J W Jukema; A F Stalenhoef; C J D Ross; B C Carleton; J J P Kastelein; M R Hayden
Journal:  Pharmacogenomics J       Date:  2011-01-18       Impact factor: 3.550

3.  Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Authors:  George K Dresser; David G Bailey; Brenda F Leake; Ute I Schwarz; Paul A Dawson; David J Freeman; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

4.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

Authors:  I Tamai; J Nezu; H Uchino; Y Sai; A Oku; M Shimane; A Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

5.  Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.

Authors:  R G Tirona; B F Leake; G Merino; R B Kim
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

6.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

7.  Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.

Authors:  N Ichimaru; S Takahara; Y Kokado; J D Wang; M Hatori; H Kameoka; T Inoue; A Okuyama
Journal:  Atherosclerosis       Date:  2001-10       Impact factor: 5.162

Review 8.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Authors:  Rhiannon N Hardwick; Craig D Fisher; Mark J Canet; George L Scheffer; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2011-08-30       Impact factor: 3.922

10.  Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.

Authors:  April D Lake; Petr Novak; Craig D Fisher; Jonathan P Jackson; Rhiannon N Hardwick; D Dean Billheimer; Walter T Klimecki; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2011-07-07       Impact factor: 3.922

View more
  16 in total

1.  Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Mark J Canet; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

2.  Oatp1a1 requires PDZK1 to traffic to the plasma membrane by selective recruitment of microtubule-based motor proteins.

Authors:  Wen-Jun Wang; John W Murray; Allan W Wolkoff
Journal:  Drug Metab Dispos       Date:  2013-10-10       Impact factor: 3.922

3.  Synergistic interaction between genetics and disease on pravastatin disposition.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Andrew J Lickteig; Michael J Goedken; Curtis D Klaassen; Nathan J Cherrington
Journal:  J Hepatol       Date:  2014-03-05       Impact factor: 25.083

4.  Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-01-02       Impact factor: 3.922

Review 5.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

Review 6.  Organic anion-transporting polypeptides.

Authors:  Bruno Stieger; Bruno Hagenbuch
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

7.  Functional expression of the 11 human Organic Anion Transporting Polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate.

Authors:  Izabel Patik; Daniella Kovacsics; Orsolya Német; Melinda Gera; György Várady; Bruno Stieger; Bruno Hagenbuch; Gergely Szakács; Csilla Özvegy-Laczka
Journal:  Biochem Pharmacol       Date:  2015-09-28       Impact factor: 5.858

8.  Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.

Authors:  Veronika Buxhofer-Ausch; Lena Secky; Katrin Wlcek; Martin Svoboda; Valentinos Kounnis; Evangelos Briasoulis; Andreas G Tzakos; Walter Jaeger; Theresia Thalhammer
Journal:  J Drug Deliv       Date:  2013-02-03

Review 9.  Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury.

Authors:  Winfried Krueger; Urs A Boelsterli; Theodore P Rasmussen
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

10.  Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.

Authors:  Anne T Nies; Mikko Niemi; Oliver Burk; Stefan Winter; Ulrich M Zanger; Bruno Stieger; Matthias Schwab; Elke Schaeffeler
Journal:  Genome Med       Date:  2013-01-11       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.